Clinical Trial Update: PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating pegylated interferon alfa-2b in young patients with plexiform neurofibroma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Neoplasm of Uncertain Malignant Potential, Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED